BNP Paribas Arbitrage SA lifted its stake in shares of Haemonetics Corporation (NYSE:HAE) by 53.4% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 27,603 shares of the medical instruments supplier’s stock after buying an additional 9,607 shares during the quarter. BNP Paribas Arbitrage SA owned about 0.05% of Haemonetics worth $1,239,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of HAE. Shine Investment Advisory Services Inc. purchased a new stake in shares of Haemonetics during the 2nd quarter worth approximately $132,000. Riverhead Capital Management LLC lifted its position in shares of Haemonetics by 79.3% during the 2nd quarter. Riverhead Capital Management LLC now owns 3,407 shares of the medical instruments supplier’s stock worth $135,000 after buying an additional 1,507 shares during the last quarter. Pacad Investment Ltd. purchased a new stake in shares of Haemonetics during the 2nd quarter worth approximately $174,000. Shelton Capital Management purchased a new stake in shares of Haemonetics during the 2nd quarter worth approximately $204,000. Finally, Cubist Systematic Strategies LLC purchased a new stake in shares of Haemonetics during the 2nd quarter worth approximately $260,000.

Shares of Haemonetics Corporation (NYSE HAE) traded up $0.12 during trading on Wednesday, hitting $58.63. 545,000 shares of the stock were exchanged, compared to its average volume of 352,522. The firm has a market cap of $3,090.00, a PE ratio of 36.06, a price-to-earnings-growth ratio of 4.42 and a beta of 0.91. Haemonetics Corporation has a fifty-two week low of $36.44 and a fifty-two week high of $58.99. The company has a quick ratio of 1.51, a current ratio of 2.17 and a debt-to-equity ratio of 0.22.

Haemonetics (NYSE:HAE) last announced its earnings results on Tuesday, November 7th. The medical instruments supplier reported $0.48 EPS for the quarter, beating analysts’ consensus estimates of $0.41 by $0.07. The business had revenue of $225.40 million for the quarter, compared to analysts’ expectations of $219.12 million. Haemonetics had a net margin of 0.50% and a return on equity of 11.16%. The company’s quarterly revenue was up 2.3% on a year-over-year basis. During the same period in the previous year, the company posted $0.38 EPS. equities analysts expect that Haemonetics Corporation will post 1.7 EPS for the current year.

HAE has been the topic of a number of recent research reports. Zacks Investment Research raised shares of Haemonetics from a “hold” rating to a “buy” rating and set a $52.00 target price on the stock in a report on Wednesday, October 25th. Morgan Stanley lifted their target price on shares of Haemonetics from $43.00 to $51.00 and gave the company an “equal weight” rating in a report on Thursday, November 9th. TheStreet raised shares of Haemonetics from a “c” rating to a “b-” rating in a report on Monday, August 7th. Barrington Research lifted their target price on shares of Haemonetics from $48.00 to $57.00 and gave the company an “outperform” rating in a report on Wednesday, November 8th. Finally, Craig Hallum reaffirmed a “hold” rating and issued a $50.00 target price (up from $40.00) on shares of Haemonetics in a report on Wednesday, November 8th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $53.33.

In other Haemonetics news, CAO Dan Goldstein sold 4,691 shares of the business’s stock in a transaction on Monday, November 13th. The shares were sold at an average price of $54.93, for a total value of $257,676.63. Following the transaction, the chief accounting officer now directly owns 3,747 shares of the company’s stock, valued at approximately $205,822.71. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Susan Bartlett Foote sold 16,926 shares of the business’s stock in a transaction on Friday, November 10th. The shares were sold at an average price of $54.19, for a total transaction of $917,219.94. Following the completion of the transaction, the director now directly owns 27,313 shares in the company, valued at $1,480,091.47. The disclosure for this sale can be found here. Insiders sold a total of 40,250 shares of company stock worth $2,196,240 over the last three months. 1.20% of the stock is currently owned by corporate insiders.

ILLEGAL ACTIVITY WARNING: This story was posted by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The legal version of this story can be read at https://www.dailypolitical.com/2017/11/29/haemonetics-corporation-hae-stake-increased-by-bnp-paribas-arbitrage-sa.html.

Haemonetics Profile

Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.

Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Corporation (NYSE:HAE).

Institutional Ownership by Quarter for Haemonetics (NYSE:HAE)

Receive News & Ratings for Haemonetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.